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Introduction
Breast lesions are found with increasing frequency,
both within the breast screening service and in
symptomatic and high-risk patients. Currently, tis-
sue diagnoses of clinically palpable or imaging de-
tected lesions are obtained percutaneously. Fine
needle aspiration (FNA) and automated core biopsy
are commonly employed because they are low cost,
easily accessible and less technically demanding. In
recent years, directional, vacuum-assisted biopsy
(VAB) devices have gained popularity because of
their advantages over conventional biopsy methods.
These advantages include the ability to obtain larger
amount of tissues with contiguous specimens, the
possibility of acquiring multiple specimens with sin-
gle insertion of a needle, a more accurate diag-
nosis with a lower cancer miss rate and lower
histological underestimates [1–5] and the replace-
ment of excisional removal of benign lesions [6]. In
this review article, we discuss the role of VAB in
breast care, techniques and practical tips in per-
forming successful ultrasound-guided VAB, and the
role of VAB in complete removal of benign lesions
such as fibroadenomas. We also compare VAB with
other biopsy devices, examine the advantages and
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disadvantages of various types of VAB devices, and
discuss new products.
What is vacuum-assisted biopsy?
A directional, vacuum-assisted biopsy device has 
a side aperture at the distal end of the needle for
acquisition of the specimen (Fig. 1). It operates by
using a vacuum to pull tissue into the sampling
notch; an inner cutter is then driven in to cut
through the breast tissue. The specimen is then
transported outside the breast into a specimen 
collection chamber by vacuum. Contiguous sam-
ples are obtained by rotating the needle with the
position of the aperture pointing towards a dif-
ferent clock position. Suction is applied again to
capture another specimen. In this way, multiple
specimens are retrieved without the need for 
needle re-insertion.
Because the amount of specimen retrieved by
VAB is large, there is the possibility of complete re-
moval of imaging findings such as breast nodules
or calcifications. If the pathology of the sampled
specimens is positive for malignancy, further surgi-
cal excision is required. Therefore, it is essential to
have the index lesion localized after VAB proce-
dures by placing a localization marker.
At present, there are three commonly used mod-
els in the market: ATEC (Suros Surgical Systems Inc.,
Indianapolis, Indiana, USA), EnCor (SenoRx, Alizo
Viejo, California, USA) and Mammotome (Ethicon
Endo-Surgery, Cincinnati, Ohio, USA). All of these
VAB devices operate by the same principle of suc-
tion mechanism but the design of the devices is
different. All of these systems can be used for sono-
graphic and stereotactic procedures. In addition, the
new models are all magnetic resonance imaging
compatible.
Use of vacuum-assisted biopsy
It has been suggested by breast cancer experts that
minimally invasive breast biopsy should be encour-
aged in place of traditional open surgical breast
biopsy to detect malignancies whenever possible
[7]. Moreover, VAB is recommended over other
biopsy techniques because of the larger specimen
size which aids in reliable lesion categorization by
pathologists.
VAB provides diagnostic samples of breast tissue
for histological examination by partial or complete
removal of the imaging abnormality. Its main use is
sampling of probably benign or suspicious, clinically
palpable or non-palpable but imaging-detectable
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Fig. 1. Tip of a vacuum-assisted biopsy (VAB) needle. VAB is
a directional biopsy device with a side aperture for acquisition
of breast tissue. The vacuum holes are located at the opposite
side of the sampling aperture.
Table 1. Procedures for ultrasound-guided vacuum-
assisted biopsy
• Position the patient correctly: supine for medial
lesions and contralateral posterior oblique for lateral
lesions; patient raises the ipsilateral arm;
• Identify the lesion with ultrasound;
• Plan the needle approach;
• Inject local anesthetics around the lesion and then
under the lesion to elevate it from the chest wall;
• Make a skin incision of approximately 4–6 mm;
• Hold the ultrasound transducer with your left hand
(non-dominant) and advance the VAB probe with
your right hand, advance the VAB probe posterior
(deep) to the lesion;
• Confirm the lesion is over the sampling chamber by
retracting the cutter to expose the aperture;
• Perform tissue acquisition between 9 & 3 o’clock
until the lesion is completely removed;
• Place the localizing marker;
• Provide post biopsy care.
breast lesions. These can be sonographic abnormal-
ities (such as a solid mass, a complex cystic mass,
abnormal shadowing and distorted glandular le-
sions), or mammographic lesions (such as calcifi-
cations, mass or distortion), or magnetic resonance
imaging detected mass or non-mass enhancing lesions.
Because a larger amount of tissue can be obtained
by VAB compared with other methods, it is partic-
ularly useful in the biopsy of small and indefinite
lesions that may be missed by other biopsy tech-
niques. It is also useful in suspicious lesions that are
associated with surgical scars, fibrosis or prosthetic
implants. VAB offers the benefit of complete removal
of image-detected lesions and microcalcifications.
However, because of its higher cost compared with
FNA or core biopsy, VAB is commonly the second
line of biopsy method employed in some centers. In
such cases, VAB is performed only after inadequate
or inconclusive cytology or histology, or when there
are discordant imaging-pathology results from pre-
vious FNA or core biopsies.
Apart from the diagnostic indications, VAB is also
a recognized method of therapeutic removal of be-
nign lesions such as fibroadenomas [6]. The use of
percutaneous VAB can reduce the need for open sur-
gical biopsy or excision, and minimize costs of the
operating theatre or hospital stays associated with
surgical excision.
There is no known absolute contraindication 
to this clinic-based percutaneous biopsy tech-
nique. However, because of the larger amount of
tissue being harvested, the risk of hematoma for-
mation is still a concern. If a patient has bleeding
diathesis, or is undergoing anticoagulant therapy,
core biopsy would be performed instead. Thus,
VAB is only performed when the coagulation pro-
file is normal.
If a breast lesion is detected by one modality 
of imaging methods, VAB can be performed under
the guidance of that imaging modality. If a lesion
is detected by both an ultrasound scan and 
mammogram, then ultrasound-guided VAB is recom-
mended as the procedure of choice. Ultrasound-
guided VAB is more comfortable for the patient as
there is no need for breast compression and usu-
ally fewer specimens need to be taken. It is less
time consuming, no radiation is involved and there
is more flexibility in the placement for a cosmetic
incision. In addition, there is visual reassurance of
complete lesion removal during a real time ultra-
sound scan.
Because of the possibility of complete removal
of the imaging abnormality that may need further
surgical intervention, we routinely deploy a localiz-
ing marker after the VAB procedure. In practice, if
a patient refuses to have a localization marker put
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Table 2. Comparison between core biopsy and vacuum-assisted biopsy
Core biopsy Vacuum-assisted biopsy
Firing mechanism Suction mechanism
• Pin point accuracy is required • Ability to acquire tissue outside the “line of fire”
• Difficult for deep lesions, breast implants & • Can be used for deep lesions, breast implants & 
thin breasts thin breasts
Need to withdraw & re-insert needle for each sample Acquires multiple specimens with a single insertion
Sutureless
Occasional problem in tissue sampling Larger size of specimens
Underestimation Allows contiguous sampling
Less underestimation
With more specimens, proportion of blood to tissue goes up Able to draw blood from biopsy cavity
Only sampling, unable to completely remove Total removal of imaging abnormality possible, 
imaging abnormality may prevent decision dilemma in follow up
Cheap Expensive
in after VAB, we advise the patient to have core
biopsy instead of VAB.
Procedures and practical tips in performing
ultrasound guided vacuum-assisted biopsy
A high quality ultrasound machine is essential for 
a successful ultrasound-guided VAB procedure. A
high frequency (7.5–12.0 MHz) linear array trans-
ducer with focus from 2–3 mm to 3 cm and beam
profile with a small section thickness no thicker than
2–3 mm are required to detect subtle breast lesions.
The transducer used should have a transducer size
and shape ergonomically suited to long period of
scanning. The position of the patient should be
supine with the ipsilateral side elevated. The pa-
tient’s arm should be raised with the hand of the
same arm placed under the head.
The lesion is identified with an ultrasound scan.
The route for insertion of the needle is then plan-
ned. Skin preparation with an aseptic technique 
is followed. Local anesthesia (1% lignocaine with
1:100,000 adrenaline) is applied under the skin,
along the track to the lesion, around the lesion,
and lastly, posterior (deep) to the lesion to elevate
the lesion away from the chest wall (Fig. 2). A
small incision of approximately 4–6 mm is made.
The left (non-dominant) hand holds the ultra-
sound transducer, while the right (dominant) hand
holds the VAB device to advance to needle poste-
rior (deep) to the lesion. The cutter is then re-
tracted to expose the sampling aperture to check
whether the lesion is on top of the sampling cham-
ber, which can be identified by the “ring-down”
artifacts of vacuum holes and discontinuity at the
anterior wall of the VAB needle (Fig. 3). Tissue ac-
quisition can then be obtained from the 3 o’clock
to 9 o’clock positions. During tissue sampling, the
lesion can be seen diminished in size after repeated
cuttings (Fig. 4). After the lesion is completely re-
moved sonographically, a localizing marker is placed
at the biopsy site. Hemostasis is then achieved by
digital pressure, an ice pack and a pressure garment.
Correct positioning of the patient is an important
step for a successful ultrasound-guided VAB proce-
dure. For lesions located at the lateral aspect of the
breast, the patient should be placed in a supine posi-
tion with the ipsilateral side elevated. The degree
of obliquity depends on the size of the breast and
the degree of breast flow. For medial lesions, the
obliquity may be less and sometimes it is better to
place the patient in a supine position.
To decide the path of needle insertion, the gen-
eral rule of taking the shortest path to the lesion is
applied. For cosmetic reasons, the Langer lines of
the breast can be approximated with the needle
path and the skin incision is preferably at the lower
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Fig. 2. Local anesthesia (arrows) is injected posterior (deep)
to the lesion (arrow heads) to elevate the lesion from the chest
wall. This procedure is essential for deep lesions that are close
to the chest wall.
Fig. 3. Correct positioning of the vacuum-assisted biopsy needle.
The sampling aperture is open and the nodule is seen just
above the sampling notch. Note the “ring-down” artifacts from
the vacuum holes at the sampling notch (arrows).
part or upper outer quadrant of the breast so that
the patient can choose to wear a low-cut garment
without an obvious skin wound or scar at the 
upper inner quadrant of the breast.
Because the mechanism of the biopsy system is
to generate a vacuum environment within the sam-
pling area, we recommend that the length of the
skin incision should be no larger than the thickness
of the needle, or suitable negative pressure within
the breast cannot be achieved and a quality speci-
men cannot be retrieved. 
When dealing with lesions within tough fibrous
breast tissue, it may be very difficult for the VAB nee-
dle to pierce through the breast. The problem can
be resolved by using the “hydrodissection” tech-
nique, by injecting local anesthesia along the needle
path when withdrawing the local anesthetic needle
to create a passageway between fibrous breast tis-
sues. This procedure allows an easier insertion of the
VAB needle within the dense fibrous breast tissue.
Deep lesions pose technical difficulties for VAB.
For successful biopsy of deep lesions, the lesions
should be positioned at the far end of the ultra-
sound transducer, while the skin entry site of the
VAB needle should be placed away (usually 1–3 cm)
from the near end of the transducer. This allows the
VAB needle probe to be placed at a more horizontal
position and more parallel to the chest wall. In this
way, the risk of needle puncture to the chest wall is
minimized. The lesion needs to be elevated by a
copious amount of local anesthesia to separate it
from the chest wall (Fig. 2). The non-dominant fin-
gers may also help to push behind the lesion to
elevate it from the chest wall. The VAB needle probe
is then advanced posterior (deep) to the lesion and
the probe is levered more horizontally. Tissue acqui-
sition can then be made anterior to the VAB probe.
The use of the left (non-dominant) hand serves
multiple purposes during the procedure. We use the
thumb and index finger to hold the transducer,
while the middle, ring and little fingers push the
lesions from the back, elevate deep lesions, allow
controlled forward advancement of the VAB probe,
and assist in better positioning of the lesion with-
out the need for repositioning of the VAB probe.
With regard to the choice of needle size, for le-
sions smaller than 1 cm in size, a 10- or 11-gauge
needle is used. For those lesions larger than 1 cm, a
7- or 8-gauge needle can be used to acquire a larger
specimen size and achieve a faster procedure.
Discussion
The goal of percutaneous breast biopsy is to safely
obtain accurate tissue diagnosis. There are, how-
ever, concerns about the costs and speed of the
various procedures, and also comfort to the pa-
tients or operators. VAB offers a good balance of all
these requirements for breast biopsy.
The accuracy of a biopsy technique is measured
by the cancer miss rate, histological underestimates,
as well as calcification retrieval failure. Because a
false negative rate is related to the gauge of the
needle, we routinely use a 7-gauge to 11-gauge nee-
dle and do not use 14-gauge VAB needles [1,2].
Jackman et al [2] reported that false negative diag-
noses of stereotactic VAB were made in 4.4% of
cases using a 14-gauge needle, while there were
only 0.45% of cases using an 11-gauge needle.
The reported cancer miss rate of 11-gauge VAB is
approximately 0–3.3% [8–11], which is consis-
tently lower than that of a 14-gauge core biopsy of
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Fig. 4. The lesion was partially removed during vacuum-assisted
biopsy. Note that the inner cutting blade (arrow) is cutting the
lesion.
4% [12] and comparable to a needle localized breast
biopsy of 2.5% [3]
Histological underestimates can be either a
ductal carcinoma in situ (DCIS) underestimate or
atypical ductal hyperplasia (ADH). A DCIS underes-
timate is defined as a percutaneous biopsy yielding
DCIS but it has an invasive component at subse-
quent surgery. An ADH underestimate is defined as
a percutaneous biopsy yielding ADH but it has a
DCIS or invasive component at subsequent surgery.
The significance of ADH and DCIS underestimates
is that they affect treatment choice, extent and
prognosis. For ultrasound guided biopsy, Simon et
al [13] and Parker et al [14] reported no histologic
underestimates in their studies in which they used
11-gauge VAB to examine 71 and 124 sonographic
lesions, respectively. Philpotts et al [15] also showed
a very low histological underestimate of 1%. Histo-
logical underestimates found in ultrasound-guided
biopsy are consistently lower than that of stereo-
tactic-guided biopsy, in which the DCIS and ADH
underestimates are 20% and 44%, respectively, for
the 14-gauge core biopsy system, and 11% and
19%, respectively, for 11-gauge VAB [4, 5]. This
finding is not unexpected since the odds of diag-
nosing ADH and DCIS are much higher by stereo-
tactic biopsy because these lesions are commonly
presented as calcifications in mammograms rather
than sonographic nodules.
Although this review focuses on the role of VAB
in ultrasound, VAB is important in the retrieval of
mammographically visible calcifications. VAB is asso-
ciated with less calcification retrieval failure com-
pared with core biopsy. One of the reasons for this
finding is that VAB has the ability to retrieve a larger
amount of breast tissue (approximately 100 mg
per sample) than 14-guage core biopsy (approxi-
mately 15 mg per sample) [16]. The ability to ob-
tain contiguous specimens, with more tissue with
less blood and more tissue per unit time, is also
attributed to the better calcification retrieval rate
compared with core biopsy. Jackman and Rodriguez-
Soto [17] reported that 16% negative specimen
radiographs using 14-gauge core biopsy and only
1% using 11-gauge VAB. The likelihood of detecting
calcifications histologically is significantly higher
and the probability of making a specific histopatho-
logic diagnosis is also significantly higher if calcifi-
cations are present on specimen radiographs [18].
Dershaw et al [19] reported that carcinoma was
identified in four (57%) of seven women who un-
derwent surgical biopsy after unsuccessful stereo-
tactic large-core biopsy of calcifications. In another
study reported by Kwok et al [20], the cancer miss
rate was 40% in a group of patients with inconclu-
sive percutaneous pathology with failed calcifica-
tion retrieval. Therefore, with the use of the VAB
device, a more accurate diagnosis can be achieved,
with cancer being missed less often, less histological
underestimates, less calcification retrieval failure and
subsequently fewer repeat biopsies.
With regard to safety issues, VAB is reported to
have a very low complication rate. While bruising
is common after biopsy or even after needle punc-
ture for the taking of blood, significant hemato-
mas requiring surgical intervention after VAB are
very rare. Parker et al [14] reported the occurrence
of significant hematomas in less than 1% of VAB,
and none required surgical intervention. Kettritz 
et al [21] reported that 25 of 2,874 cases (<1%)
had hematoma formation. One of these cases re-
quired surgical drainage and another four cases had
persistent bleeding requiring surgical intervention
(0.17%) [21]. This finding is comparable to using a
14-gauge core biopsy needle as shown in a multi-
institutional study by Parker et al [22], who reported
hematoma formation requiring surgical drainage
in 3 of 3,765 cases (0.08%). Although the risk of
hematoma formation with VBA is low, significant
bleeding can be avoided if it is determined prior to
the procedure whether the patient is currently on
anticoagulation drugs or has a history of bleeding
tendency. Kwok et al [20] recommend two meth-
ods to reduce the amount of bleeding during bio-
psy. First, by careful selection of the puncture site
to avoid blood vessels on pre-procedural stereo-
tactic images for stereotactic biopsy or turning on
color Doppler signals on ultrasound guided biopsy.
Second, use local anesthetics with diluted adren-
aline to reduce bleeding. Moreover, minimizing the
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size of skin incisions and taking only the essential
number of cores of representative tissues are general
principles to reduce bleeding during biopsy [20].
Infection after VAB is very rare. Parker et al [16]
reported that less than 0.10% of patients develop
infection and require antibiotic treatment. Kettritz
et al [21] reported that 0.17% of patents had mas-
titis requiring antibiotics. The complication rate of
infection requiring antibiotic treatment (0.08%) is
similar to that of VAB in the 14-gauge core biopsy
study [22]. Measures to avoid infection include
proper sterile technique during biopsy and good
wound care post-biopsy.
For ultrasound-guided biopsy of deep lesions
near the chest wall, VAB is more preferable than
core biopsy despite the fact that VAB uses a larger-
sized needle. This is because the firing mechanism
of core biopsy requires adequate dead space for the
needle to pass distal to the lesion, while manual in-
sertion of the VAB needle without firing decreases
the chance of perforation of the chest wall.
There have been many studies addressing the
theoretical concern of epithelial displacement dur-
ing percutaneous biopsy [23–29]. Diaz et al showed
that the incidence and amount of tumor displace-
ment along the needle track after percutaneous
biopsy is inversely related to the interval between
biopsy and excision, indicating that the displaced
cells were rarely implanted or viable [25]. More-
over, tumor displacement would not be a problem
if the malignancy is treated with mastectomy. If the
patient is treated with breast conservation surgery,
the needle track is usually excised with the tumor
bulk and radiation therapy is followed. Therefore,
with appropriate treatment, local recurrence related
to needle track seeding along the percutaneous
biopsy needle is extremely rare. In addition, the
risk of vacuum-assisted biopsy is much lower than
that of core biopsy or FNA. The reason for this is
because when multiple passes are made with core
biopsy and FNA, cancer cells are possibly dragged
along the track with each pass. Meanwhile, only
one pass is made with vacuum assisted biopsy.
With regard to the issue of cost, the use of VAB is
associated with a higher capital cost such as vacuum
generators and biopsy hand-pieces as well as a
higher running cost of the consumables, including
needles, tubing and localizing markers, compared
with that of automated core biopsy. From a health-
care management perspective, the use of expen-
sive equipment has to be justified to outweigh the
additional costs. The ability of VAB to remove a
larger amount of breast tissue with a more accu-
rate diagnosis, to have fewer calcification retrieval
failures with fewer repeat biopsies, and to relieve
symptoms and remove imaging abnormalities are
all benefits that can spare the patient from a surgi-
cal procedure that requires an even higher cost.
VAB is a faster procedure to perform compared
with core biopsy. This is because single insertion of
a VAB needle can obtain multiple specimens and
each cutting offers a larger amount of tissue. Core
biopsy, however, needs multiple needle insertions
for retrieving multiple tissue cores. Despite the fact
that a biopsy procedure is faster in VAB, prepara-
tion (including setting up its vacuum canister and
tubing, and testing the VAB machine) takes longer
than the easy set up of the core biopsy system
whereby only placing a needle inside the biopsy
gun is required.
The VAB procedure is faster, easier and more
comfortable for patients compared with open sur-
gical excision. VAB is a clinic-based percutaneous
procedure using only local anesthesia, and usually
takes only few minutes to 20 minutes, while an
open surgical procedure needs to be performed in
an operating theatre, is usually under general anes-
thesia and takes a longer time to perform, includ-
ing the anesthetic time.
The National Health Service of the United
Kingdom has endorsed the use of image-guided
VAB to remove benign breast lesions such as fibro-
adenomas [6]. This is usually performed via ultra-
sound guidance because visualization of complete
lesion removal can be assured under real time
ultrasound. Sperber et al [30] have reported that
lesions <2.0 cm can be completely excised; Baez
et al [31] have reported that lesions <1.5 cm can
be completely excised. In our experience, we can
achieve complete removal of sonographic lesions
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measuring <1.8 cm using an 8-gauge or 7-gauge
needle. This less invasive and less deforming pro-
cedure can spare the patient from an open surgical
biopsy or excision.
There are a number of differences when com-
paring core biopsy with VAB. For accurate lesion
sampling, core biopsy requires the lesion at the “line
of fire”, and thus pin-point accuracy is mandatory.
VAB, on the other hand, is a directional device,
and thus it does not require the lesion to lie along
the path of the needle. Instead, it is better to posi-
tion the needle next to the lesion so that the sam-
pling chamber can be placed in the direction of the
lesion. The automated core biopsy devices operate
by rapid firing of the inner stylet portion of the
needle and the outer cannula portion in two very
fast steps. This requires the operator to allow room
for the excursion of the needle behind the lesion.
Therefore, core biopsy is more difficult to perform
for deep lesions near the chest wall as well as breast
lesions in patients with breast implant, since the
risks of puncturing the chest wall and rupturing
the implant capsule are higher. VAB does not need
to fire and can be driven in deep to a lesion or next
to the lesion. Therefore, biopsy is safer in those
lesions near the chest wall or within augmented
breasts. Because of the need for excursion of core
biopsy needles, stereotactic biopsy in patients with
a thin breast is technically difficult. Use of VAB can
solve this problem because it does not need to fire
and the exposed sampling aperture can be half
closed to maintain a vacuum. With each sample
retrieved by core biopsy, the device needs to be
removed and reinserted for the next pass. This is
not necessary for the VAB device, and multiple
specimens can be obtained by single needle inser-
tion. Compared with VAB, the specimens of core
biopsy are smaller, with more histological underes-
timates and the smaller lesions could be missed.
VAB can obtain a large specimen size with contigu-
ous tissue, resulting in less underestimates and less
cancer being missed; this is particularly good for
small lesions. For core biopsy, which involves more
passes for a lesion, the proportion of bloody speci-
mens is higher. VAB consistently achieves quality
samples because of its ability to draw blood from
the biopsy cavity. Moreover, core biopsy can only
sample part of the imaging abnormality, while VAB
can completely remove the imaging abnormality,
resulting in less diagnostic dilemmas during follow
up of the patients. Despite the various advantages
of VAB, it is a more expensive biopsy method than
core biopsy. The differences are tabulated in Table 2.
The Intact Breast Lesion Excision System (Intact
Medical, Natick, Massachusetts, USA), which is a
newer percutaneous vacuum-assisted biopsy device,
using radiofrequency energy rather than conven-
tional mechanical cutter, is now generally avail-
able. It is an automated breast biopsy device that
uses radiofrequency to create a path within the breast
to the lesion. This is particularly useful in patients with
dense fibroglandular breast. When the tip of the
biopsy device (wand) is advanced to the lesion, the
radiofrequency-enabled wires will deploy from 
the wand to circumscribe the lesion like a basket
and the captured specimen is retrieved by remov-
ing the wand. Vacuum is applied to remove gases
or liquids that are collected at the tip of the wand
during the procedure. The procedure can be per-
formed under either sonographic or stereotactic
guidance, in an outpatient, clinic-based setting under
local anesthesia. It enables the removal of an intact
specimen upon single entry of the biopsy device.
In a study by Sie et al, the ADH and DCIS underes-
timates were reported to be 9.4% and 5.2% [32].
These data appear promising, but the data were
based on only a limited number of cases. In addi-
tion, there are also limitations of using this device
in patients with a thin breast, and for those lesions
near the chest wall or close to the skin, as there is
risk of muscle or skin burn. Further reports are
needed for the evaluation of this new device.
Conclusion
VAB is fast and simple to perform, with a very low
complication rate. It can provide high quality spec-
imens with an accurate diagnosis. Its versatility en-
ables its use in challenging cases such as those deep
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lesions near the chest wall. It can reduce the overall
costs of breast disease diagnosis when compared
with open surgical biopsy and spares the patients
from surgical removal of benign tumors such as
fibroadenomas. Understanding the principles, know-
ing the specifics for operating VAB machines, proper
training and auditing the operator’s performance
are the key to the successful use of VAB for the care
of patients with breast lesions.
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